Clinical Trials
22 trialsNCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT05968599 2026-02-25
A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer
Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT06072196 2025-12-31
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT07086651 2025-12-08
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
Pfizer
Completed
NCT05202301 2025-08-11
A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely
Bayer
Completed
NCT06013475 2025-06-12
DEAR-EXT
Bayer
Completed
NCT06151418 2025-06-04
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
Pfizer
Completed
NCT05612880 2025-01-09
Physical Function During ARSI Treatment
UNC Lineberger Comprehensive Cancer Center
Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT02669771 2024-11-21
Long-Term Specified Drug Use-Results Survey for Xtandi Capsule
Astellas Pharma Inc
Completed
NCT03328364 2024-11-21
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Astellas Pharma Inc
Completed
NCT02495974 2024-10-21
PREMISE
Astellas Pharma Inc
Completed
NCT05520138 2024-09-27
Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Pfizer
Completed
NCT06204302 2024-04-09
ARENA
Bayer
Completed
NCT05362149 2024-03-20
DEAR
Bayer
Completed
NCT04290611 2023-04-13
VENDY
Groupe Hospitalier Pitie-Salpetriere
Completed
NCT03896984 2021-12-29
PHENIX
Bayer
Completed
NCT02353715 2020-12-24
PEAX
Duke University
Completed
NCT02471469 2020-10-19
ILUMINATE
Radboud University Medical Center
Completed
NCT02228265 2020-09-28
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
OHSU Knight Cancer Institute
Completed